Exercise of Options, Issue of Equity and TVR

RNS Number : 5539C

Instem plc

12 October 2022

 

12 October 2022

Instem plc

("Instem" or "the Company")

Exercise of Options, Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it was notified on 11 October 2022 that an employee of the Company exercised share options ("Share Options") over 27,500 ordinary shares of 10 pence each in the Company ("Ordinary Shares").

Issue of Equity and Admission

Application will be made to the London Stock Exchange for the admission of the 27,500 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 17 October 2022.  

Total voting rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,704,308 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,704,308.

The figure of 22,704,308 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Instem plc	via Walbrook
Singer Capital Markets (Nominated Adviser & Joint Broker)	[phone]
Peter Steel Rachel Hayes Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Ben Maddison
Alex Price
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome

About Instem  

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END

 

 

IOEFLFEDIILLLIF